41 – 50 of 631
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Health care utilization following "digi-physical" assessment compared to physical assessment for infectious symptoms in primary care
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Aspects of Complement Activation in Thrombocytopenic Disorders
2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B : Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
(
- Contribution to journal › Article
-
Mark
New Inhibitors in the Ageing Population : A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Thrombotic risk determined by rare and common SERPINA1 variants in a population-based cohort study
(
- Contribution to journal › Article
-
Mark
Platelet function testing : Current practice among clinical centres in Northern Europe
(
- Contribution to journal › Article
-
Mark
Bone mineral density in haemophilia – a multicentre study evaluating the impact of different replacement regimens
(
- Contribution to journal › Article